Avi

@nvpatkar Congratulations sir 🎉👏

Honoured to be a part of the #CAM (Classification Advancement Meeting) in Chicago from 18 to 20 March. We proposed a classification of blood cancers which will inform the WHO for the HAEM6 Met so many stalwarts in the field 🤩 I was a part of the #AML core committee

@nvpatkar @Gaurav_C42 @bagalbp @DrGauravNarula @lingarajnayak Congratulations sir 👏🎉

New from our group in @JClinPath by Dr Narasimha K This is an argumentative paper where we state: Should KMT2A-PTD be recognized as an AML-MR-defining abnormality? jcp.bmj.com/content/early/… @Gaurav_C42

And >50% of those 9 % will send their kids abroad, rest will have their own hospitals and could use some help with the family business. Grateful for the work I do, but I didn’t let my sister consider medicine, and understand why my friends don’t want their kids to take it up either. There are better and easier ways of earning money if you have the intelligence. And medico legal threats, high burn out and mental health disorders are making it harder for those who do it just for service and purpose.

#Hematology Advancing the classification of hematolymphoid neoplasms together: for patients, medicine, and science #lymsm #lymphoma ashpublications.org/blood/article/…

@nvpatkar @Kajari16 @cookyscan1 @drsuyash @RadioGraphics Congratulations 👏

@Kajari16 @cookyscan1 @drsuyash @RadioGraphics Congrats 👏👏

Much obliged to receive this recognition from #Radiographics for 2025. Thank you @cookyscan1 @drsuyash @RadioGraphics

@nvpatkar @JCOGO_ASCO @Gaurav_C42 @bagalbp @lingarajnayak Congratulations sir 👏

New Publication from our lab led by Dr Gojiri Mawalankar Validation and Refinement of the European LeukemiaNet 2022 Genetic Risk Stratification of AML | @JCOGO_ASCO @Gaurav_C42 @bagalbp @lingarajnayak ascopubs.org/doi/10.1200/GO…

@SanjeevGuptaDM @NitinJainMD @nvpatkar @docmparihar @drssreejesh @RanjitKSMD @PrashantTembha1 @sanamloghavi Congratulations sir 🎉

British Journal of Haematology | Wiley Online Library onlinelibrary.wiley.com/doi/abs/10.111… MUC4 regulation by IKZF1 and its implications @NitinJainMD @nvpatkar @docmparihar @drssreejesh @RanjitKSMD @PrashantTembha1 @sanamloghavi

What does it take to achieve the highest level of human performance? Across athletics, science, chess, and music @ScienceMagazine science.org/doi/10.1126/sc…

@pankajch37 @TataMemorial @ACTREC_TMC Congratulations sir 🎉

Thrilled to be among the top 10 researchers in oral cancer and in the top 0.05% of all scholars worldwide according to the 2025 ScholarGPS. @TataMemorial @ACTREC_TMC scholargps.com/scholars/10319…

2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working Party ashpublications.org/blood/article/…

Molecular subtypes of DLBCL: are we ready to translate our knowledge into the change of treatment paradigms? ashpublications.org/hematology/art… #lymsm #ASH25

Every academic oncologist should spend 1 week seeing patients in the community. I suspect after this experience their research ideas may change to things that are more practical and doable in the real world.

@SanjeevGuptaDM @DrArunCMC Congratulations 🎉

@DrArunCMC Congratulations 💐💐

Happy to have presented our work on multiomic profiling to predict response and resistance to CAR T cell therapy in lymphoma. #ASH25 #lymsm

@SanjeevGuptaDM @NitinJainMD @nvpatkar @drssreejesh @docmparihar @RanjitKSMD Congratulations sir

onlinelibrary.wiley.com/doi/10.1111/ij… Targeted NGS in high-risk B-ALL...for fusions, IKZF1 deletions, CRLF2 expression @NitinJainMD @nvpatkar @drssreejesh @docmparihar @RanjitKSMD

Infections in cancer. Addressed 10 key issues. @TataMemorial @ACTREC_TMC @VanitaNoronha @SuyogCancer @Amolpatel_dr @DrNikitaMehra @cspramesh @IJMPOofficial @bagalbp @SirohiBhawna @ajumathew_ ecancer.org/en/journal/art…

@MirghSumeet @Gaurav_C42 @CancerMedicine Congratulations 👏

Just published in @CancerMedicine 15 years of PBSC mobilization experience in Myeloma Even in the CAR-T era, collecting sufficient PBSCs is crucial. - GCSF+plerixafor comparable to chemo mobilization - If prior RT (to hematopoietic sites - spine, pelvis), chemo-mobn is better

@lingarajnayak @TheLancet @TataMemorial Congratulations 🎉👏

A LMIC perspective on managing adverse events in haematological malignancy. Privileged to lead this @TheLancet paper with authors from Argentina, Brazil, Zambia and Kenya. A wonderful experience. @TataMemorial thelancet.com/journals/lanha…

@SyedKHasan1 @ACTREC_TMC @CRI_ACTREC @SocietyofHemOnc @EHA_Hematology @BloodAdvances Congratulations sir

Sunday reading with your coffee! thehindu.com/sci-tech/rare-… @ACTREC_TMC @CRI_ACTREC @SocietyofHemOnc @EHA_Hematology @BloodAdvances

@drssreejesh @DrPMPGI @Charanpreet_14 @drpulkitrastogi @DrGPrakash @drsharmapgi @ManuJamwal25 @Agilent Congratulations sir

Our recent publication on Targeted RNAseq in B-ALL. link.springer.com/article/10.100… @DrPMPGI @Charanpreet_14 @drpulkitrastogi @DrGPrakash @drsharmapgi @ManuJamwal25 @Agilent #Leukemia #RNAseq #hematology #Bioinformatics

@SyedKHasan1 @Gaurav_C42 @ACTREC_TMC @AML_Hub @BloodAdvances @BloodJournal @CRI_ACTREC @TataMemorial Congratulations 👏

Huge congratulations to my amazing student-friends for their outstanding work! CRISPR-Cas system is set to revolutionize cancer diagnostics. Proud of this brilliant team! @ACTREC_TMC @AML_Hub @BloodAdvances @BloodJournal @CRI_ACTREC @TataMemorial